United Therapeutics Reports Fourth Quarter and Annual 2007 Financi... (

United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results

Date:2/19/2008

- Total Annual Revenues of $210.9 Million

- Annual EPS of $0.94 per Basic Share, or $0.88 per Diluted Share - Annual EBITDASO of $4.03 per Basic Share, or $3.81 per Diluted Share

SILVER SPRING, Md., Feb. 19 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced financial results for the fourth quarter and year ended December 31, 2007.

"We are pleased to report that United Therapeutics' revenues for the year ended December 31, 2007, totaled $210.9 million," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "This is the sixth straight year our revenues have grown by more than 30%. Our EBITDASO (earnings before interest, taxes, depreciation, amortization and stock option expense) for the year were $85.5 million, or $4.03 per basic share."

Net income for the three months ended December 31, 2007, was $2.0 million or $0.09 per basic share, as compared to $55.5 million or $2.54 per basic share for the three months ended December 31, 2006. EBITDASO for the three months ended December 31, 2007, was $24.7 million or $1.14 per basic share, as compared to $18.7 million or $0.81 per basic share for the three months ended December 31, 2006. Net income for the year ended December 31, 2007, was $19.9 million or $0.94 per basic share, as compared to $74.0 million or $3.21 per basic share in 2006.

Results

Revenues. Revenues grew to $210.9 million for the year ended December 31, 2007, as compared to $159.6 million for the year ended December 31, 2006, an increase of 32%. Gross margins from sales were $186.5 million, or 89%, in 2007, which is consistent with gross margins from sales of $142.6 million, or 89%, in 2006. T
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. United States Patent Office Grants CryoCors Request for Patent Interference
2. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
3. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
4. Nycomeds Ciclesonide to be Commercialised in the United States by Sepracor
5. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
6. Neptune Technologies receives GRAS notification in the United States
7. Essilor: New Acquisitions in the United States and Brazil
8. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
9. Medical Services Begins Working With United States Companies for Distribution of Its Products
10. United Therapeutics Reports Third Quarter 2007 Financial Results
11. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States

Post Your Comments:

United Therapeutics Reports Fourth Quarter and Annual 2007 Financi...( - Total Annual Reven...)